Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin for prevention of gastrointestinal toxicity during pelvic radiotherapy
IRCT20200825048515N36Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of atorvastatin in gastrointestinal toxicity (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Gastrointestinal toxicity. Started Aug 2021; status: completed.
02
Drugs
atorvastatin
03
Conditions
gastrointestinal toxicity
Beyond the preview
Go deeper on IRCT20200825048515N36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200825048515N36.